Michael Weening - 31 Jan 2025 Form 4 Insider Report for CALIX, INC (CALX)

Role
President & CEO, Director
Signature
/s/ Tom Gemetti as Attorney-in-Fact for Michael Weening
Issuer symbol
CALX
Transactions as of
31 Jan 2025
Net transactions value
$0
Form type
4
Filing time
04 Feb 2025, 16:17:45 UTC
Previous filing
15 Aug 2024
Next filing
18 Feb 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction (CALX) Stock Option (right to buy) Award $0 +125,737 $0.000000 125,737 31 Jan 2025 Common Stock 125,737 $34.26 Direct F1
transaction (CALX) Stock Option (right to buy) Award $0 +80,325 $0.000000 80,325 31 Jan 2025 Common Stock 80,325 $34.26 Direct F2
transaction (CALX) Stock Option (right to buy) Award $0 +217,500 $0.000000 217,500 31 Jan 2025 Common Stock 217,500 $39.68 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 8, 2024, the reporting person was granted a performance-based stock option to purchase 262,500 shares of common stock. On January 31, 2025, the Talent and Compensation Committee (the Committee) of the Board of Directors of Calix, Inc. (Calix) determined that the performance criteria governing 47.9% of the grant had been achieved, resulting in 125,737 shares of common stock remaining subject to the option. The option vests: (i) as to 25% of the shares of common stock subject to the option, on February 8, 2025; and (ii) as to the remaining 75% of the shares of common stock subject to the option, quarterly in equal installments over 36 months from February 8, 2025, subject to continued employment with Calix through the applicable vesting dates.
F2 On February 8, 2024, the reporting person was granted a performance-based option to purchase 87,500 shares of common stock. On January 31, 2025, the Committee determined that the performance criteria governing 91.8% of the grant had been achieved, resulting in 80,325 shares of common stock remaining subject to the option. The option vests: (i) as to 25% of the shares of common stock subject to the option, on February 8, 2025; and (ii) as to the remaining 75% of the shares of common stock subject to the option, quarterly in equal installments over 36 months from February 8, 2025, subject to continued employment with Calix through the applicable vesting dates.
F3 The option vests: (i) as to 25% of the shares of common stock subject to the option, on January 31, 2026; and (ii) as to the remaining 75% of the shares of common stock subject to the option, quarterly in equal installments over 36 months from January 31, 2026, subject to continued employment with Calix through the applicable vesting dates.